AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
🌍 Cross-language spread
PULSE detected this story across 4 language editions of the world's news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include AskTraders, Breakingthenews.net, Bloomberg and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 106d ago.
Quick answers
Why is "AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (18)
- AstraZeneca-Bristol Myers: Brace for a Biotech M&A Boom Barron's · 105d ago
- The $400bn megadeal brewing in big pharma Financial Times · 105d ago
- AstraZeneca and Bristol-Myers Squibb in talks over potential merger Yahoo Finance · 105d ago
- AstraZeneca Is Said to Have Explored Bristol Myers Merger Bloomberg.com · 105d ago
- AstraZeneca, BMS reportedly in $400B merger talks FirstWord Pharma · 106d ago
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb CNBC · 106d ago
- AstraZeneca Explored Buying Bristol Myers in Potential Mega Merger Bloomberg.com · 106d ago
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger The Guardian · 106d ago
- AstraZeneca said to have explored Bristol Myers merger Fortune · 106d ago
- AstraZeneca plots £300bn tie-up with US rival Yahoo Finance · 106d ago
- AstraZeneca, Bristol Myers are in talks about merger Endpoints News · 106d ago
- AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports Reuters · 106d ago
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports CNBC · 106d ago
- AstraZeneca in Talks to Merge with Bristol Myers Squibb AskTraders · 106d ago
- AstraZeneca, Bristol Myers could strike merger deal Breakingthenews.net · 106d ago
- AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says Bloomberg · 106d ago
- AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE) Seeking Alpha · 106d ago
- AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up Financial Times · 106d ago
Topics
Related trends
New drug could be cure for common cause of high blood pressure
EU medicines panel recommends AstraZeneca's baxdrostat for uncontrolled hypertension, while new research suggests a potential cure for hormone-driven high blood pressure.
New treatment may cure common hormonal cause of high blood pressure
A small study found that extended treatment with the aldosterone synthase inhibitor baxdrostat led to sustained blood pressure reduction for up to two years after patients stopped taking the drug.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca reportedly made a $10 billion acquisition offer for obesity drugmaker Rhythm Pharmaceuticals.
How Maya Jama went from Bristol native to Celebrity Traitors star
Maya Jama garners widespread praise for a generous charity donation following a high-stakes betrayal in the finale of Celebrity Traitors.
AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
AstraZeneca unveils a $1.5 billion savings drive, pledges no layoffs and sees profits surge, sparking a bullish CEO outlook and a share‑price rally.
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is showcasing a new portfolio of targeted cancer therapies, featuring a stomach cancer drug that significantly extended patient survival times.